Drug Trial Radar · NCT00879658
Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis
Last checked: Nov 20, 2026Latest source record: Jan 13, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
297
Actual
Start
Mar 30, 2009
Primary completion
May 4, 2011
Study completion May 4, 2011
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Apr 10, 2009
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to determine the dose-response curve for the MRI-based efficacy of BAF312 compared with placebo in patients with Relapsing-Remitting Multiple Sclerosis (RRMS), and to characterize its safety and tolerability for the selection of an optimal dose in a later phase III study. Study Design Rationale An adaptive design was chosen to characterize the dose response curve of BAF312. In a first period of study ("Period 1"), three doses of BAF312 and placebo were tested for MRI efficacy. Based on an interim analysis (IA) after 3 months of treatment, two additional active doses for period 2 wereselected , thus allowing to optimize the overall determination of the dose response curve with 5 data points of active treatment, and placebo. The doses were kept blinded. The use of Modeling and Simulation allowed to establish the full range and dynamics of the dose-response curve in silico, and hence the definition of the optimal dose for later phase III studies. The choice of placebo as treatment control was essential to obtain information on the specific compared to non-specific effects of active treatment and provides the best way of evaluating the efficacy and of assessing the true safety and tolerability profile of BAF312. Short-term placebo exposure (6 (Period 1) or 3 (Period 2) months, respectively) was unlikely to lead to longer term differences in outcomes \[Polman, 2008\]. The use of an adaptive design strategy contributed to a significant reduction of placebo exposure, both in terms of the number of patients and duration, as compared to conventional trial models. Patients having completed the study within the protocol might be eligible for the Extension Phase study where they receive long-term BAF312 treatment (a separate protocol).
Conditions
- Relapsing-remitting Multiple Sclerosis
Interventions
BAF312Drug
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Responsiveness of BAF312 Based on the Number of Combined Unique Active MRI Lesions (CUAL)Time frame: 3 months of treatment
Locations
72 sites in 12 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Cullman, Alabama
Novartis Investigative Site
San Francisco, California
Novartis Investigative Site
Centennial, Colorado
Novartis Investigative Site
Miami, Florida
Novartis Investigative Site
Pompano Beach, Florida
Novartis Investigative Site
Tallahassee, Florida
Novartis Investigative Site
Tampa, Florida
Novartis Investigative Site
Chicago, Illinois
Novartis Investigative Site
Elk Grove Village, Illinois
Novartis Investigative Site
Grand Rapids, Michigan
Novartis Investigative Site
Raleigh, North Carolina
Novartis Investigative Site
Akron, Ohio
Novartis Investigative Site
Pittsburgh, Pennsylvania
Novartis Investigative Site
Greenville, South Carolina
Novartis Investigative Site
Seattle, Washington
Novartis Investigative Site
Milwaukee, Wisconsin
Novartis Investigative Site
Vancouver, British Columbia, Canada
Novartis Investigative Site
Ottawa, Ontario, Canada
Novartis Investigative Site
Gatineau, Quebec, Canada
Novartis Investigative Site
Greenfield Park, Quebec, Canada
Novartis Investigative Site
Montreal, Quebec, Canada
Novartis Investigative Site
Helsinki, Finland
Novartis Investigative Site
Tampere, Finland
Novartis Investigative Site
Turku, Finland
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Dresden, Germany
Novartis Investigative Site
Freiburg im Breisgau, Germany
Novartis Investigative Site
Leipzig, Germany
Novartis Investigative Site
Lengerich, Germany
Novartis Investigative Site
München, Germany
Novartis Investigative Site
Münster, Germany
Novartis Investigative Site
Wiesbaden, Germany
Novartis Investigative Site
Budapest, Hungary
Novartis Investigative Site
Budapest, Hungary
Novartis Investigative Site
Debrecen, Hungary
Novartis Investigative Site
Veszprém, Hungary
Novartis Investigative Site
Montichiari, BS, Italy
Novartis Investigative Site
Chieti, CH, Italy
Novartis Investigative Site
Milan, MI, Italy
Showing 40 of 72 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.